These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16799407)

  • 61. Molecular Aspects of Insulin Aggregation and Various Therapeutic Interventions.
    Das A; Shah M; Saraogi I
    ACS Bio Med Chem Au; 2022 Jun; 2(3):205-221. PubMed ID: 37101572
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The intriguing dose-dependent effect of selected amphiphilic compounds on insulin amyloid aggregation: Focus on a cholesterol-based detergent, Chobimalt.
    Siposova K; Petrenko VI; Garcarova I; Sedlakova D; Almásy L; Kyzyma OA; Kriechbaum M; Musatov A
    Front Mol Biosci; 2022; 9():955282. PubMed ID: 36060240
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Insulin Pump-related Inpatient Admissions in a National Sample of Youth With Type 1 Diabetes.
    Everett EM; Copeland TP; Moin T; Wisk LE
    J Clin Endocrinol Metab; 2022 May; 107(6):e2381-e2387. PubMed ID: 35196382
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inflammation at Site of Insulin Infusion Diminishes Glycemic Control.
    Kesserwan S; Lewis BE; Mao L; Sharafieh R; Atwood T; Kreutzer DL; Klueh U
    J Pharm Sci; 2022 Jul; 111(7):1952-1961. PubMed ID: 34986358
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Poewe W; Stocchi F; Arkadir D; Ebersbach G; Ellenbogen AL; Giladi N; Isaacson SH; Kieburtz K; LeWitt P; Olanow CW; Simuni T; Thomas A; Zlotogorski A; Adar L; Case R; Oren S; Fuchs Orenbach S; Rosenfeld O; Sasson N; Yardeni T; Espay AJ;
    Mov Disord; 2021 Nov; 36(11):2687-2692. PubMed ID: 34496081
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study.
    Olanow CW; Espay AJ; Stocchi F; Ellenbogen AL; Leinonen M; Adar L; Case RJ; Orenbach SF; Yardeni T; Oren S; Poewe W;
    J Parkinsons Dis; 2021; 11(1):177-186. PubMed ID: 33164945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Wirelessly Controlled Implantable System for On-demand and Pulsatile Insulin Administration.
    Lee SH; Ahn JW; Cho YC; Kim SN; Lee C; Ku GW; Bin Choy Y; Kim HC
    Sci Rep; 2019 Mar; 9(1):5009. PubMed ID: 30899066
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Continuous Glucose Monitoring Enables the Detection of Losses in Infusion Set Actuation (LISAs).
    Howsmon DP; Cameron F; Baysal N; Ly TT; Forlenza GP; Maahs DM; Buckingham BA; Hahn J; Bequette BW
    Sensors (Basel); 2017 Jan; 17(1):. PubMed ID: 28098839
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of Insulin Amyloid Fibrillation by a Novel Amphipathic Heptapeptide: MECHANISTIC DETAILS STUDIED BY SPECTROSCOPY IN COMBINATION WITH MICROSCOPY.
    Ratha BN; Ghosh A; Brender JR; Gayen N; Ilyas H; Neeraja C; Das KP; Mandal AK; Bhunia A
    J Biol Chem; 2016 Nov; 291(45):23545-23556. PubMed ID: 27679488
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Continuous Subcutaneous Insulin Infusion Needle Break.
    George MM; Ruiz-Elizalde AR; Beck JK
    Clin Diabetes; 2015 Oct; 33(4):195-7. PubMed ID: 26487795
    [No Abstract]   [Full Text] [Related]  

  • 71. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fault detection and safety in closed-loop artificial pancreas systems.
    Bequette BW
    J Diabetes Sci Technol; 2014 Nov; 8(6):1204-14. PubMed ID: 25049365
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey.
    Pickup JC; Yemane N; Brackenridge A; Pender S
    Diabetes Technol Ther; 2014 Mar; 16(3):145-9. PubMed ID: 24180294
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Insulin pump therapy in children with type 1 diabetes: the dark side of the moon.
    Scaramuzza AE; Dell'Acqua M; Macedoni M; Zuccotti GV
    J Diabetes Sci Technol; 2013 Jul; 7(4):1095-7. PubMed ID: 23911194
    [No Abstract]   [Full Text] [Related]  

  • 75. Intrinsic fibrillation of fast-acting insulin analogs.
    Woods RJ; Alarcón J; McVey E; Pettis RJ
    J Diabetes Sci Technol; 2012 Mar; 6(2):265-76. PubMed ID: 22538135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates.
    Kerr D; Morton J; Whately-Smith C; Everett J; Begley JP
    J Diabetes Sci Technol; 2008 May; 2(3):450-5. PubMed ID: 19885209
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.
    Jeitler K; Horvath K; Berghold A; Gratzer TW; Neeser K; Pieber TR; Siebenhofer A
    Diabetologia; 2008 Jun; 51(6):941-51. PubMed ID: 18351320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Technical risks with subcutaneous insulin infusion.
    Guilhem I; Leguerrier AM; Lecordier F; Poirier JY; Maugendre D
    Diabetes Metab; 2006 Jun; 32(3):279-84. PubMed ID: 16799407
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
    Buczkowska EO; Dworzecki T; Wiedermann G; Malanowicz B; Szot D
    Przegl Lek; 2005; 62(1):49-53. PubMed ID: 16053222
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.